Medicare is overpaying for generic drugs
Medicare is the single largest provider of health insurance in the United States, serving 63.8 million senior citizens as of 2022. Three-quarters of these recipients are enrolled in… read more.
Medicare is the single largest provider of health insurance in the United States, serving 63.8 million senior citizens as of 2022. Three-quarters of these recipients are enrolled in… read more.
Eli Lilly and Company announced that the FDA approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with chronic lymphocytic leukemia or… read more.
A reduction in nurses coming in from the European Union as a result of Brexit may have cost the NHS an estimated £61.9 million per year, according to… read more.
UCB announced that the European Commission (EC) has granted a marketing authorization for Zilbrysq (zilucoplan) as an add-on to standard therapy for the treatment of generalized myasthenia gravis… read more.
How do emergency department staff determine whether older adults who have fallen need imaging? A new decision rule will help emergency department physicians determine which older adults need… read more.
Societal issues — including the growth in ultra-high-cost treatments, the epidemic of mental health and substance use disorders, climate change, and the rise of artificial intelligence (AI)— could… read more.
Vivos Therapeutics, Inc. announced that it has been granted 510(k) clearance from the FDA for treating severe obstructive sleep apnea (OSA) in adults using the Vivos’ removable CARE… read more.
More older Americans use cannabis now than before the pandemic, with 12% saying they’ve consumed a THC-containing substance in the past year and 4% saying they do so… read more.
To improve primary care, Canada can learn from Organisation for Economic Co-operation and Development (OECD) countries with high rates of patients attached to primary care clinicians, write authors… read more.
AstraZeneca has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate) . The decision was made due to substantially increased enrolment… read more.
As the use of wearable technology grows, smart watches are marketed across the globe to consumers as a way to monitor health. For some, they’re told by these… read more.
Results of a qualitative research study into the uptake of PrEP – a drug which stops HIV infecting the body – suggests that more needs to be done… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
